FDA Approval Status Update for Deutetrabenazine by Aurobindo Pharma
Aurobindo Pharma's application for deutetrabenazine has been submitted and is under standard review.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Movement Disorders
Company: Aurobindo Pharma
Asset: deutetrabenazine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Aurobindo Pharma
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's review of Aurobindo Pharma's application for deutetrabenazine is significant as it marks the company's entry into the competitive movement disorders market. This could impact pricing strategies and market dynamics for existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the progress of the FDA review and any subsequent market entry timelines.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.